Eizen Joshua M 4

4 · AN2 Therapeutics, Inc. · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

AN2 Therapeutics (ANTX) COO Joshua M. Eizen Receives Repriced Options

What Happened

Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics (ANTX), was reported on Form 4 to have received two derivative awards (options) and simultaneously recorded matching dispositions to the issuer on March 19, 2026. The transactions are shown as: 92,000 derivative shares (grant and disposition) and 50,150 derivative shares (grant and disposition). These actions reflect a board-approved repricing of options rather than an open-market purchase or sale of common stock.

Key Details

Transaction date: March 19, 2026; Form filed March 23, 2026 (filed after the 2-business-day window).
Repriced exercise price: $3.91 per share (footnote 1). All other option terms remain unchanged except as described in the filing.
Vesting: The 92,000-share option vests 25% on the 9/29/2022 anniversary with the remainder monthly over the next 36 months (footnote 2). The 50,150-share option vests 1/48 each month beginning Jan 1, 2023 (footnote 4).
Premium End Date: The repriced exercise price may be reverted to the original exercise price under certain conditions before the Premium End Date (earliest of Sept 19, 2027; a change in control; or the reporting person’s death/disability) (footnote 1).
Filing timeliness: The Form 4 was filed four days after the transaction date (appears late relative to the 2-business-day Form 4 requirement).
Shares owned after the transaction: Not specified in the provided filing excerpt.

Context

These were derivative-option transactions (A = grant/acquisition of a derivative; D = disposition to issuer). The matching grant and disposition entries, together with the footnotes stating the board approved a repricing, indicate an exchange/repricing of existing option awards rather than a cash exercise, open-market sale, or gift.
For retail investors: repricings adjust the strike price of options and can affect potential future dilution and executive incentives; they are not direct indications of an insider buying or selling company stock.

Form 4

Period: 2026-03-19

See Remarks

Transactions

Award
Stock Option (right to buy)
[F1][F3][F2]
2026-03-19+92,000→ 92,000 total
Exercise: $3.91Exp: 2032-10-13→ Common Stock (92,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F3][F2]
2026-03-19−92,000→ 0 total
Exercise: $17.88Exp: 2032-10-13→ Common Stock (92,000 underlying)
Award
Stock Option (right to buy)
[F1][F3][F4]
2026-03-19+50,150→ 50,150 total
Exercise: $3.91Exp: 2033-02-14→ Common Stock (50,150 underlying)
Disposition to Issuer
Stock Option (right to buy)
[F3][F4]
2026-03-19−50,150→ 0 total
Exercise: $14.29Exp: 2033-02-14→ Common Stock (50,150 underlying)

Footnotes (4)

[F1]The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.
[F2]The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date.
[F3]On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.
[F4]The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.

Signature

/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen|2026-03-23

1 file